Track orders, get results, manage your info, and more.
Order tests, track orders, get results, and more.
Exact Sciences
Mute the noise.
Spotlight the signal.
Using whole-genome sequencing and MAESTRO technology,1 the next-generation Oncodetect® MRD test spotlights very faint signals to help inform treatment decisions.2,3
We're united by a shared purpose: helping people live fuller lives through better health. Together, we will transform the way cancer is detected, diagnosed and managed for more people around the world.
We’re fighting cancer every step of the way
So that everyone feels confident about their path forward
We help bring clarity to cancer
Cancer creates so many uncertainties. We’re committed to answering questions, solving problems, and making a lasting, positive impact on people's lives. Our tests explore hereditary risks, screen for cancer’s presence, and examine the unique genomic alterations of an individual’s cancer after a diagnosis to help guide their treatment.
Everything starts with people
We’re focused on patients, providers, doctors, researchers, and caregivers. Our medical experts partner with the industry’s best minds and collaborate with top institutions, advocacy partners, and policymakers to help change lives and transform how the world approaches cancer.
A breast cancer surgeon's breast cancer journey
Hear how genomic testing helped Deepa and her doctor make an informed decision to forgo chemotherapy.*
Convenient testing made early detection easy
Watch how testing at home helped Leigh Anne take the first step in diagnosing and treating her colon cancer before it progressed.
Fueling breakthroughs in cancer care
Our experience and process set us apart. Life-changing science. Deep expertise. Strong collaboration. State-of-the-art labs. Rigorous research. The result? Proven accuracy, better potential outcomes, and continuous progress in the fight against cancer.
Putting big ideas into action
Discover our DNA through our latest announcements and stories.
The Power in Numbers
Colorectal cancer survivors unite at the Cologuard Classic by Exact Sciences to celebrate their triumphs, build community
Become part of something meaningful
Changing lives and achieving our purpose starts with our team and their commitment to fighting cancer. Are you ready to make a difference? Explore open positions and learn why Exact Sciences has been a certified Great Place To Work® for seven years running
Get in touch
Questions or comments? Find customer support, company contacts, and location information all in one place.
Reference and footnotes
In addition to being an Oncotype DX® Ambassador, Deepa occasionally serves in a professional capacity as a paid consultant of Exact Sciences. These services are unrelated to this activity.
Tsvetanova B, et al. Association for Molecular Pathology 2025 Annual Meeting Abstracts. J Mol Diagn. 2025;27 Suppl:S113.
Messinger J, Martinez B, Tsvetanova B, et al. Analytical performance characterization of a whole genome tumor-informed molecular residual disease test. Poster presented at: AMP 2025 Annual Meeting & Expo; November 11-15, 2025; Boston, MA.
Dooley et al. Evaluation of whole-exome and whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial. J Clin Oncol. 44, 570-570(2026).DOI:10.1200/JCO.2026.44.16_suppl.570